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Adenosine is generated in increased concentrations at
sites of injury/hypoxia and mediates a variety of
physiological and pharmacological effects via G pro-
tein–coupled receptors (A1, A2A, A2B, and A3). Because
all adenosine receptors are expressed on osteoclasts,
we determined the role of A2A receptor in the regula-
tion of osteoclast differentiation. Differentiation and
bone resorption were studied as the macrophage col-
ony-stimulating factor-1–receptor activator of NF-B
ligand formation of multinucleated tartrate-resistant
acid phosphatase (TRAP)–positive cells from primary
murine bone marrow–derived precursors. A2A recep-
tor and osteoclast marker expression levels were
studied by RT-PCR. Cytokine secretion was assayed by
enzyme-linked immunosorbent assay. In vivo exami-
nation of A2A knockout (KO)/control bones was de-
termined by TRAP staining, micro–computed tomog-
raphy, and electron microscopy. The A2A receptor
agonist, CGS21680, inhibited osteoclast differentia-
tion and function (half maximal inhibitory concen-
tration, 50 nmol/L), increased the percentage of im-
mature osteoclast precursors, and decreased IL-1
and tumor necrosis factor- secretion, an effect that
was reversed by the A2A antagonist, ZM241385. Ca-
thepsin K and osteopontin mRNA expression in-
creased in control and ZM241385-pretreated oste-
oclasts, and this was blocked by CGS21680. Micro–
computed tomography of A2AKO mouse femurs
showed a significantly decreased bone volume/tra-
becular bone volume ratio, decreased trabecular num-
ber, and increased trabecular space. A2AKO femurs
showed an increased TRAP-positive osteoclast. Electron
microscopy in A2AKO femurs showed marked oste-
oclast membrane folding and increased bone resorp-
tion. Thus, adenosine, acting via the A2A receptor, inhib-
its macrophage colony-stimulating factor-1–receptor
activator of NF-B ligand–stimulated osteoclast differen-
tiation and may regulate bone turnover under condi-tions in which adenosine levels are elevated. (Am J
Pathol 2012, 180:775–786; DOI: 10.1016/j.ajpath.2011.10.017)
Communication between osteoclasts and osteoblasts is
essential for bone modeling and remodeling. In bone
remodeling, bone formation and resorption are at equi-
librium. The principal mechanism for bone remodeling,
between bone resorption and formation, lies in the se-
quential nature of the process by which osteoblasts refill
resorption lacunae with an equivalent amount of os-
teoid.1,2 When this balance is disturbed in favor of bone
resorption, the result is pathological bone destruction, as
observed in osteoporosis3 or inflammatory diseases,
such as rheumatoid arthritis.4
Osteoclasts degrade bone to initiate normal bone re-
modeling and mediate bone loss in pathological condi-
tions by increasing their resorptive activity. Osteoclasts
are multinucleated giant cells, derived from myeloid pre-
cursors belonging to the monocyte/macrophage fam-
ily,5,6 that secret hydrochloric acid and proteases, such
as cathepsin K and tartrate-resistant acid phosphatase
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stroying and resorbing both the mineral and matrix com-
ponents of bone simultaneously.7 The initial event asso-
ciated with osteoclast commitment requires interaction
with the hematopoietic growth factor, macrophage colo-
ny-stimulating factor (M-CSF)-1, which acts via its recep-
tor. Further commitment, differentiation, and activation of
osteoclasts are mediated by a complex network of regu-
latory factors, including systemic hormones, locally pro-
duced cytokines, and cell-cell and cell-matrix interac-
tions that are required for transition of the osteoclast
precursor (OCP) into a multinucleated and fully activated
osteoclast.8,9 Among these factors, receptor activator of
NF-B ligand (RANKL) is critical for the stimulation of
osteoclast differentiation and activation.10–14 RANKL
binds to its receptor, RANK, on the surface of OCPs,
activating signaling through NF-B, c-Fos, phospho-
lipase C, and nuclear factor of activated T cells c1
(NFATc1), to induce differentiation of OCPs into oste-
oclasts.9
Adenosine, the metabolic product of adenine nucleo-
tide dephosphorylation, is generated intracellularly and
extracellularly from the catabolism of adenine nucleo-
tides in response to stress, such as hypoxia and inflam-
matory injury. Ectonucleotidases, of which the apyrase
CD39 and the 5=-nucleotidase CD73 are prominent ex-
amples, are present on the extracellular surface of many
tissues and are crucially involved in numerous important
functions, primarily via generation of adenosine.15 These
enzymes rapidly and effectively shift signaling by releas-
ing adenine nucleotides and their products to signaling
through adenosine receptors. Extracellular adenosine
regulates a variety of physiological processes via inter-
action with specific cell surface receptors. Adenosine
receptors are members of the large superfamily of G
protein–coupled receptors. Four subtypes are recog-
nized: A1, A2A, A2B, and A3 receptors, each of which has
a unique pharmacological profile and is present in virtu-
ally every tissue and cell type.16 The adenosine A1 and
A2 receptors were initially subdivided on the basis of their
effects on adenylyl cyclase activity, inhibition and stimu-
lation, respectively,17,18 via coupling to Gi and Gs pro-
teins, respectively; the A2B receptor is coupled to Gq,
whereas the A3 receptor is Gi coupled. Recently, evi-
dence was presented that the A2A receptor may be cou-
pled to different G proteins in different areas and a variety
of downstream signaling pathways, including cAMP-de-
pendent, phospholipase C–dependent, and stimulation
or inhibition of extracellular signal regulated kinase 1/2
via the cAMP-ras-MEK1 pathway have been implicated in
signaling at this receptor.19–23
The study of the role of adenosine and adenosine
receptors in the regulation of cells involved in bone me-
tabolism and turnover has only recently begun. We have
previously reported that both adenosine A1 and A2A re-
ceptors play an important role in promoting human mono-
cyte fusion into giant cells in vitro.24 Moreover, we have
found that deletion or blockade of adenosine A1Rs leads
to increased bone density and prevents ovariectomy-
induced bone loss without affecting bone formation,25and we demonstrated that adenosine A1 receptor activa-tion is required for appropriate formation and function of
osteoclasts in vitro.26
Because we have previously reported that A2A recep-
tor occupancy inhibits fusion of stimulated human mono-
cytes to form giant cells in vitro, in this study, we deter-
mined whether there was a similar effect of A2A receptor
occupancy on osteoclast formation and function both in
vitro and in vivo and potentially identified novel ap-
proaches for the prevention of bone loss.
Materials and Methods
Reagents
Recombinant mouse RANKL and M-CSF were obtained
from R&D Systems (Minneapolis, MN). CGS21680 and
ZM241385 were obtained from Tocris (Ellisville, MO). 
minimal essential medium (-MEM; Gibco, Invitrogen,
Carlsbad, CA) was used for all incubations, supple-
mented with 10% fetal bovine serum (Invitrogen), 100
IU/mL penicillin, and 100 g/mL streptomycin (Invitro-
gen). Paraformaldehyde (PFA), sodium acetate, glacial
acetic acid, naphthol AS MX phosphate disodium salt,
Fast Red Violet LB, and Fluoroshield with DAPI were from
Sigma-Aldrich (St. Louis, MO), and sodium tartrate was
from Fisher Scientific (Pittsburgh, PA). The BD BioCoat
Osteologic Bone Cell Culture System was from BD Bio-
sciences (San Jose, CA). Silver nitrate and sodium car-
bonate were from Sigma-Aldrich, and sodium carbonate
was obtained from Fisher Scientific. Alexa Fluor 555–
phalloidin was obtained from Invitrogen.
Animals
Adenosine A2A receptor knockout (A2AKO) mice were a
gift from Dr. Jiang Fan Chen (Boston University School of
Medicine, Boston, MA).27 Female A2AKO mice were bred
onto a C57BL/6 background (10 backcrosses) in the
New York University School of Medicine Animal Facility.
Mice described as wild type (WT) were all maintained on
the C57BL/6 background by the breeder (Taconic Lab-
oratories, Albany, NY). Genotyping was performed by
PCR, as previously reported.28–30 The WT C57BL/6 mice
were used as a control. All protocols were approved by
the New York University School of Medicine Institutional
Animal Care and Use Committee.
Osteoclast Differentiation from Bone Marrow
Cells
Bone marrow cells were isolated from 6- to 8-week-old
female C57BL/6 and A2AKO mice (n  6 each). Femurs
and tibiae were aseptically removed and dissected free
of adherent soft tissues. The bone ends were cut, and the
marrow cavity was flushed out with -MEM from one end
of the bone using a sterile 21-gauge needle. The bone
marrow was carefully dispersed by pipetting and incu-
bated overnight in -MEM containing 10% fetal bovine
serum to obtain a single-cell suspension. Nonadherent
cells were collected and seeded at an appropriate den-
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the BD BioCoat Osteologic Bone Cell Culture System in
-MEM with 10% fetal bovine serum and 30 ng/mL M-
CSF for 2 days. On day 3 (day 0 of differentiation), 30
ng/mL RANKL was added to the culture, together with
CGS21680 (10 mol/L to 1 nmol/L), alone or in the pres-
ence of ZM241385 (10 mol/L to 1 nmol/L). Cultures were
fed every third day by replacing half of the culture me-
dium with an equal quantity of fresh medium and re-
agents. To determine whether the effect of CGS21680 on
osteoclast formation varied with amount of exposure time,
the A2A receptor agonist was added at 10 mol/L on
consecutive days, starting on day 3 and ending 7 days
later. To correlate the effects of A2A agonist with cytokine
expression in osteoclast differentiation, TRAP staining
was performed in M-CSF–RANKL–derived osteoclasts
plated and differentiated over 7 days in the presence of
IL-1, 10 ng/mL, or tumor necrosis factor (TNF)-, 50
ng/mL, together with CGS21680 alone or with ZM241385.
Characterization of Osteoclasts in Culture
After incubation for 7 days at 37°C in a humidified atmo-
sphere of 5% CO2, wells were prepared for TRAP stain-
ing, to counteract osteoclast differentiation, or for Von
Kossa staining, to study osteoclast function (n  6 for
each assay). Briefly, for TRAP staining, cells were
washed with prewarmed PBS, fixed in 4% PFA for 10
minutes, and stained for acid phosphatase in the pres-
ence of 0.3 mol/L sodium tartrate, using naphthol AS-BI
phosphate as a substrate. To determine osteoclast func-
tion, we cultured osteoclasts, as previously described, on
the BD BioCoat Osteologic Bone Cell Culture System, a
submicron synthetic mineralized calcium phosphate thin
film coated onto culture vessels, as an alternative method
to dentin slices, for direct assessment of osteoclast ac-
tivity in vitro,31,32 following the manufacturer’s recommen-
dations, and stained the plates with Von Kossa stain. The
number of TRAP-positive multinucleated giant cells con-
taining three or more nuclei per cell was scored.33 The
Von Kossa–stained images were analyzed with Matlab
compiler software (Natick, MA). The Matlab compiler soft-
ware used to analyze Von Kossa staining to quantify in
vitro bone resorption takes an approach that is identical
to that used by such commercial software packages as
SigmaPlot. A program was developed using basic image
analysis methods, such as edge, erode, and other imag-
ing functions, to help extract the regions of interest and
quantify the osteoclastic resorption. The edge function
permitted transformation of color images into binary im-
ages, making it easier to identify and analyze the re-
sorbed areas. After selecting the image and the region of
interest, a basic threshold was applied to the images to
obtain the optimum binary quality for analysis. The total
area, which was equivalent to the total number of pixels in
the selected image, was calculated via a simple counter.
Then, the number of white pixels, which represents the
resorbed areas, was also counted via a counter, and a
percentage of the resorbed area was calculated. To fur-
ther validate the software measurement of the area of
resorption, we quantitated areas of known size and cal-culated the variance. The software performed these mea-
surements in a reproducible fashion, and the results ob-
tained accurately reflected the relative sizes of the areas
measured.
Quantitative Real-Time RT-PCR
To validate the effect of A2A receptors in osteoclast dif-
ferentiation, we measured the activation of the two oste-
oclast differentiation markers, cathepsin K and NFATc1,
together with osteopontin, an extracellular structural pro-
tein that initiates the development of osteoclast ruffled
borders, and A2A receptor by quantitative RT-PCR. WT
osteoclasts derived from bone marrow were collected
during the 7 days of differentiation, and total RNA was
extracted using the RNeasy Mini Kit (Qiagen, Invitrogen),
following the manufacturer’s protocol, including sample
homogenization with QIAshredder columns (Qiagen). To
avoid genomic DNA contamination, we performed the
on-column DNA digestion step. For first-strand cDNA
synthesis, 20 L of total RNA was retrotranscribed using
the MuLV Reverse Transcriptase PCR kit (Applied Bio-
systems, Foster City, CA) at 2.5 U/L, including the fol-
lowing reagents in the same reaction: RNase inhibitor, 1
U/L; random hexamers, 2.5 U/L; MgCl2, 5 mmol/L;
PCR buffer II, one times; and deoxyribonucleotide
triphosphates, 1 mmol/L (all from Applied Biosystems).
Relative quantification of gene expression was performed
using real-time RT-PCR on a Stratagene Mx3005P (Agi-
lent Technologies, La Jolla, CA) with Brilliant SYBR Green
Kit QPCR Master Mix (Stratagene, Agilent Technologies),
according to the manufacturer’s protocol. The following
primers were used in real-time PCR amplification: A2A
receptor, 5=-AGCCAGGGGTTACATCTGTG-3= (forward)
and 5=-TACAGACAGCCTCGACATGTG-3= (reverse); ca-
thepsin K, 5=-GCTGAACTCAGGACCTCTGG-3= (forward)
and 5=-GAAAAGGGAGGCATGAATGA-3= (reverse);
NFATc1, 5=-TCATCCTGTCCAACACCAAA-3= (forward)
and 5=-TCACCCTGGTGTTCTTCCTC-3= (reverse); osteo-
pontin, 5=-TCTGATGAGACCGTCACTGC-3= (forward)
and 5=-TCTCCTGGCTCTCTTTGGAA-3= (reverse); and
glyceraldehyde-3-phosphate dehydrogenase, 5=-CTA-
CACTGAGGACCAGGTTGTCT-3= (forward) and 5=-
GGTCTGGGATGGAAATTGTG-3= (reverse). The Pfaffl
method34 was used for relative quantification of A2A re-
ceptor, cathepsin K, and NFATc1.
Morphological Characterization of Cultured
Osteoclasts
Osteoclasts were generated from bone marrow cells ex-
tracted from the femurs and tibiae, as previously de-
scribed. To differentiate osteoclasts, bone marrow cells
were replated at 7500 cells/mL in fibronectin-coated
glass coverslips in -MEM containing 30 ng/mL M-CSF
and 30 ng/mL RANKL, in the presence or absence of the
adenosine A2A agonist, CGS21680. After 7 days in cul-
ture, cells were fixed with 4% PFA in PBS, blocked with
PBS containing 1% bovine serum albumin and 0.1% Tri-
ton X-100 for 30 minutes, stained fluorescently with Al-
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stained with DAPI (Fluoroshield with DAPI mounting
media), as previously described.35 To evaluate oste-
oclast morphological characteristics, the averages of
400 osteoclasts were examined in each sample using
confocal microscopy (Leica SP5 confocal system, Buffalo
Grove, IL).
Cytokine ELISAs
M-CSF–RANKL–derived osteoclasts were plated and differ-
entiated over 7 days, as previously described. Cell super-
natant was collected every day, centrifuged to remove any
debris, and analyzed by Quantikine ELISA kits (R&D Sys-
tems) to determine the secretion of IL-1 and TNF-. The
manufacturer’s protocol was strictly followed, and sam-
ples were run in duplicate with media-only controls and a
standard curve correlation coefficient 0.98.
Bone Histological Features
The femurs from seven C57BL/6 (WT) and seven A2AKO
mice were excised, cleaned of soft tissue, placed into
10% formaldehyde for 24 to 48 hours, and decalcified in
EDTA. Paraffin-embedded histological sections were
stained, using H&E and immunohistologic techniques, for
type I procollagen or for TRAP activity. We measured the
bone volume (BV) in a standard zone, situated at least 0.5
mm from the growth plate, excluding the primary spon-
giosa and trabeculae connected to the cortical bone, and
enumerated the osteoclasts and trabecular area in the
same zone as that used for assessing BV (original mag-
nification, 10), using BioQuant software (Nashville,
TN).36 For measuring the osteoid, we used either Von
Kossa staining (using calcified sections in methacrylate)
or Goldner trichrome staining (also on calcified sections).
Electron Microscopic Examination of
Osteoclasts
The femurs from five mice were fixed in 2.5% PFA plus
0.5% glutaraldehyde in 0.05 mol/L sodium cacodylate
buffer (pH 7.4) for 12 hours at room temperature. After
rinsing three times for 20 minutes in the same buffer, the
material was postfixed for 1 hour in 1% osmium tetroxide
(in 0.1 mol/L sodium cacodylate buffer), dehydrated in a
graded ethyl alcohol series, and embedded in Epon
(EMbed 812; Electron Microscopy Sciences, Hatfield,
PA). Thin sections (80- to 90-nm thick) of calcified bone
were collected in distilled water containing one drop of
bromothymol blue (pH 8.0), to prevent mineral disso-
lution from the thin sections. Sections were stained with
lead citrate and alcoholic uranyl acetate and examined
using a Philips CM-12 electron microscope (Phillips,
Mahwah, NJ).
Micro–X-Ray CT Analysis of Bone Mass
For measurements of the bone volume/trabecular volume
(BV/TV), the femurs of seven WT and seven A2AKO micewere measured by micro–X-ray computed tomography
(CT), as previously described,25,37 using an MS-8 scan-
ner (GE Healthcare, London, UK) at 18-m isotropic res-
olution. The scans were calibrated by air, water, and a
mineral standard material phantom and the Parker’s al-
gorithm for digital reconstruction.25,38 Parameters were
calculated using software supplied with the instrument.
Measurement of BMD
We assessed the bone mineral density (BMD; g/cm2) of
the whole skeletons of 4-month-old mice, using a PIXImus
bone densitometer (Lunar, Madison, WI). The instrument
was calibrated before each scanning session, using a
phantom with known BMD, according to the manufactur-
er’s guidelines. There were seven WT and seven A2AKO
mice anesthetized by i.p. injection of ketamine (100 g/g
of body weight) and xylazine (10 g/g of body weight)
and then placed in the prone position on the specimen
tray to allow scanning of the entire skeleton.
Statistical Analysis
Statistical significance for differences between groups
was determined by using analysis of variance or the
Student’s t-test. All statistics were calculated using
GraphPad software (GraphPad, San Diego, CA).
Results
Effect of A2A Receptor Activation in Osteoclast
Differentiation and Function in Vitro
After 7 days of osteoclast differentiation, TRAP and Von
Kossa staining were performed to counteract the role of
A2A receptor activation in the differentiation process and
in bone remodeling function in vitro. When we analyzed
the osteoclast number in WT cell cultures, we observed a
dose-dependent inhibition of osteoclastogenesis when
cultures were treated with CGS21680 alone (Figure 1A;
half maximal inhibitory concentration, 50 nmol/L; maximal
decrease of 38%  8% inhibition; P  0.05; n  6).
Interestingly, the A2A receptor agonist–mediated inhibi-
tion was more than completely reversed by pretreatment
with the selective A2A antagonist ZM241385 in the pres-
ence of 10 mol/L CGS21680 (Figure 1A). Moreover,
there was dose-dependent activation of osteoclastogen-
esis by the A2A receptor antagonist (146%  8% of con-
trol in the presence of ZM241385, 10 mol/L; P  0.05;
n  6), suggesting that endogenous adenosine inhibits
osteoclast formation in an autocrine fashion. When cells
from A2AKO mice were studied, neither the agonist nor
the antagonist, at any concentration, affected the number
of osteoclasts that formed (Figure 1B).
The effect of adenosine A2A receptor stimulation/an-
tagonism on bone resorption paralleled the effects on
osteoclast formation. CGS21680 treatment diminished
osteoclast resorption in a dose-dependent fashion (half
maximal inhibitory concentration, 0.5 mol/L; maximal
resorption of 31%  7%, where control resorption was
he resu
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effect was observed when cultures were pretreated with
ZM241385 in the presence of CGS21680, 10 mol/L, and
resorption increased in a dose-dependent manner (Fig-
ure 1A). As with osteoclast formation, neither CGS21680
nor ZM241385 treatment affected osteoid resorption by
cells from A2AKO mice (Figure 1B), confirming the results
obtained with TRAP staining.
To determine the stage of osteoclast formation and
function affected by A2A receptor stimulation, we began
treatment of cultures with CGS21680 at various time
points after the start of the cultures. We found that
CGS21680 inhibited osteoclast differentiation (Figure 2A)
and function (Figure 2B) when added to the culture at the
beginning of differentiation (days 0 to 4) but had little or
no effect when added after that time (Figure 2, A and B).
Expression of Osteoclast Differentiation Markers
in the Presence of CGS21680
To confirm A2A receptor–mediated inhibition of osteoclast
differentiation, M-CSF–RANKL–derived precursors were
collected during the 7 days of osteoclast differentiation
and RNA was extracted. We first analyzed the expression
of the A2A receptor during M-CSF–RANKL–stimulated os-
teoclast formation. As shown in Figure 3A, the expression
of A2A receptor changed over time, increasing in control
cells (up to 2.2-fold on days 2 and 4 of differentiation,
P 0.005), an effect that was abrogated in A2A receptor–
activated cells. Pretreatment with ZM241385 also re-
versed the effect of CGS21680 treatment on A2A receptor
message expression. When we analyzed the change in
mRNA expression for cathepsin K, we observed that,
both in control and ZM241385-pretreated osteoclasts,
cathepsin K was up-regulated during osteoclast differen-
tiation (up to 80-fold on day 7 for control cells and 50-fold
Figure 1. Effect of A2A receptor on osteoclast formation of mouse bone ma
fixed and stained for TRAP and Von Kossa after being cultured for 7 days, in
alone or CGS21680  ZM241385 (10 mol/L to 1 nmol/L for the ZM241385
were counted as osteoclasts (red staining). Resorbed areas (inset on each TR
were expressed as the means of four cultures. B: TRAP (red staining cells) an
KO mouse osteoclast primary culture cells and percentage of control in the
(10 mol/L to 1 nmol/L for the ZM241385 and 10 mol/L for CGS21680). T
cultures 30 minutes before CGS21680.on day 7 of differentiation for ZM241385, P  0.005), butCGS21680 reduced the increase (Figure 3B). NFATc1
mRNA expression was up-regulated during osteoclast
differentiation (up to sixfold on day 6 of differentiation,
P 0.005), and neither A2A receptor activation nor block-
ade affected the M-CSF–RANKL–induced increase in
expression (Figure 3C). Finally, mRNA expression for os-
teopontin was also up-regulated in the M-CSF–RANKL–
stimulated osteoclast alone or pretreated with ZM241385,
but CGS21680 inhibited the stimulated increase (Figure
3D). The observation that M-CSF–RANKL–induced up-
regulation of NFATc1 was unaffected by the A2A agonist
or its antagonist supports the hypothesis that A2A recep-
tor activation selectively regulates cellular function and
does not act as a general transcriptional inhibitor or cel-
lular toxin.
Morphological Characterization of Osteoclast
Cultures
As we have previously reported,26 osteoclasts cultured
on glass exhibit three distinct morphological features
(Figure 4A). The least mature osteoclasts represent an
early stage in osteoclast differentiation; are generally
small, with fewer than five centrally located nuclei sur-
rounded by a ring of F-actin; and are usually absent of
podosomes. Maturing osteoclasts are variable in size,
dendritic shaped, and contain more than five nuclei dis-
tributed throughout the cytoplasm, with podosomes lo-
cated in patches at the edge of each pseudopod, and
represent fusion intermediates because they are often
connected with other maturing cells through cytoplasmic
bridges. Finally, mature osteoclasts are large, with nu-
merous nuclei located at the periphery near the periph-
eral podosome belt. We observed that the adenosine A2A
agonist, CGS21680, increased (Figure 4, B and C) the
percentage of least-differentiated osteoclasts (from
lls and bone resorption. A: WT mouse osteoclast primary culture cells were
6-well culture plates, in the presence of CGS21680 (10 mol/L to 1 nmol/L)
mol/L for CGS21680). TRAP-positive cells containing three or more nuclei
ing image) appear in clear, with a contrasting brown background. The results
Kossa (inset on each TRAP staining image) staining analysis in A2A receptor
e of CGS21680 (10 mol/L to 1 nmol/L) alone or pretreated with ZM241385
lts were expressed as the means of four cultures. ZM241385 was added torrow ce
48- or 1
and 10
AP stain
d Von
presenc10.5%  1.0% to 72.3%  1.10% for CGS21680, P 
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ferentiated osteoclasts was reversed by the A2A antago-
nist, ZM241385 (to 17.3%  2.3%, P  0.005). There
were similar percentages of maturing cells (24.6% 
1.2% for control, 23.3%  1.8% for CGS21680, and
22.6%  3.4% for CGS21680  ZM241385) and an A2A
receptor–mediated decrease in mature osteoclasts
(64.9%  2.3% for control, 4.5%  2.0% for CGS21680,
and 60.2%  1.7% for CGS21680  ZM241385; P 
0.005). These data further confirm that the activation of
A2A receptors plays an important regulatory role in oste-
oclast fusion and differentiation.
Cytokine Secretion during Osteoclast
Differentiation
CGS21680 treatment markedly decreased concentra-
tions of IL-1 in culture supernatants during osteoclast
differentiation (Figure 5A, P  0.005), whereas pretreat-
ment with ZM241385 produced a marked increase in
IL-1 secretion starting on day 2 of differentiation and
throughout differentiation (P  0.005). In control and
Figure 2. Day response effect of CGS21680 on A2A receptor effect on
osteoclast differentiation and function. A: WT mouse osteoclast primary
culture cells stained with TRAP to counteract osteoclast differentiation being
cultured for 7 days in the presence of CGS21680, 10 mol/L, on different
days. B: WT mouse osteoclast primary culture cells to study osteoclast
function by Von Kossa staining being cultured for 7 days in the presence of
CGS21680, 10 mol/L, on different days. **P  0.01.ZM241385 pretreated cells, there was an increase inTNF- secretion over time, and treatment with CGS21680
diminished levels of this cytokine during differentiation
(Figure 5B, P  0.005). When we analyzed the levels of
IL-1 and TNF- in A2AKO cell culture supernatants, we
observed an increase in cytokine levels compared with
WT cell cultures. There was a detectable increase in
IL-1 levels by day 1 of differentiation that remained
stable during the 7 days of osteoclast differentiation and
was unaffected by any of the treatments (Figure 5C, P 
0.005), whereas the secretion of TNF- was not signifi-
cantly changed in culture supernatants during osteoclast
differentiation (Figure 5D). To determine whether the
changes in TNF- and IL-1 played a role in A2A recep-
tor–mediated regulation of osteoclast formation, we de-
termined the effect of A2A receptor stimulation on oste-
oclast formation in the presence of these two cytokines.
Interestingly, both IL-1 and TNF- completely abro-
gated the capacity of CGS21680 to inhibit osteoclast
formation in vitro (2.5%  2.9% inhibition in the presence
of IL-1 and 5.1%  4.4% inhibition in the presence of
TNF-; P  0.15; Figure 5, E and F). These observations
suggest that adenosine A2A receptor–mediated inhibition
of IL-1 and TNF-might play a role in the adenosine A2A
receptor-mediated inhibition of osteoclast formation.
Micro–X-Ray CT, Dual X-Ray Absorptiometry,
and Histomorphometric Analysis of Bone in
A2AKO Mice
To correlate the in vitro A2A receptor–mediated effects on
osteoclast differentiation and function with the in vivo ef-
fects, we studied the skeletons of A2AKO mice compared
with those of WT mice. As previously described, A2AKO
mice were similar in external appearance, body weight,
and organ weight to WT controls (data not shown). Micro–
X-ray CT analysis of femurs from WT and A2AKO mice
showed a significantly decreased BV/total volume ratio
and trabecular number in A2AKO mice (P 0.05 and P
0.001, respectively) and an increased trabecular space
(P  0.001) (Figure 6A and Table 1). Cortical bone, total
area, and the outer perimeter in A2A receptor KO mice
were similar to the WT mice (Table 1).
To better characterize the bone phenotype of A2AKO
mice, we examined the long bones of the mice histomor-
phometrically. Whole body dual X-ray absorptiometry
scanning confirmed the decreased bone mineral content
in the A2AKO mice (Figure 6A). We also observed a
significant decrease in both BMD and bone mineral con-
tent (Table 1, P  0.01). Interestingly, TRAP staining
(Figure 6B) showed an increased number of TRAP-
positive osteoclasts in the femoral metaphyses of
A2AKO mice when compared with WT mice (six fields
each from femurs of two different mice each) and a
decrease in histomorphometrically determined BV/tra-
becular BV (Figure 6C, Table 1, P  0.01), reflecting
the bone loss.
Transmission electron microscopy of bone showed an
apparent increase in osteoclast membrane folding and
bone resorption in the femurs from A2AKO mice, com-
pared with WT mice, consistent with our demonstration of
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teoclasts (data not shown).
Discussion
Previous results25,26 from our laboratory demonstrated
that osteoclasts express all four adenosine receptor sub-
types (A1, A2A, A2B, and A3). Because all four adenosine
receptor subtypes are expressed on osteoclasts, we
have examined the role of distinct adenosine receptors to
determine their roles in regulating bone physiological and
pathological characteristics. Our laboratory previously
reported that deletion or blockade of adenosine A1 re-
ceptors diminished osteoclast formation and function and
osteoclast-mediated bone loss in vitro. Adenosine A1 de-
letion or blockade led to osteopetrosis in KO mice and
inhibition of post–ovariectomy-induced bone loss, a
model for post-menopausal osteoporosis.25,26 These
findings underlined the potential therapeutic impor-
tance of adenosine receptors in regulating bone phys-
iological and pathological characteristics. Herein, we
demonstrate that adenosine A2A receptors also regu-
late osteoclast formation and function in vitro and that
deletion of these receptors leads to enhanced oste-
oclast formation and function both in vitro and in vivo,
with a resulting decline in BMD.
Our in vitro studies reveal that adenosine A2A receptor
stimulation diminished the number of differentiated
TRAP-positive cells, bone resorption by these cells, and
expression of osteoclast differentiation markers, such as
cathepsin K and osteopontin. This effect is more notablewhen the agonist was added at early stages of culture.
This observation correlates with the down-regulation in
A2A receptor mRNA that occurred during differentiation.
During differentiation, A2A receptor levels undergo no
increase after CGS21680 treatment, whereas in RANKL
alone or ZM241385-stimulated cells, the A2A receptor is
overexpressed, a phenomenon consistent with the known
effects of TNF- stimulation and stimulation of NF-B
activation on adenosine A2A receptor expression.
39–42
This, together with in vitro differentiation and function as-
says performed in A2AKO cells, suggests that the A2A
receptor has to be either activated or blocked from the
beginning of cell differentiation to exert its effect on os-
teoclast formation.
Although the KO animals studied were universal
knockouts and not specific for osteoclasts or OCPs, it is
likely that the primary effect on bone metabolism ob-
served herein is primarily the result of specific loss of
adenosine receptors on osteoclasts and their precursors.
The studies of in vitro differentiation of osteoclasts studied
herein start with a relatively pure population of myeloid
cells containing precursors that will differentiate into os-
teoclasts in the presence of M-CSF and RANKL. As
shown herein, an adenosine A2A-selective receptor ago-
nist suppresses osteoclast formation in cells from WT
mice (an effect completely reversed at pharmacologically
relevant concentrations of selective antagonists) but not
in the OCPs derived from A2A receptor KO mice. The
increase in osteoclasts observed in vivo in the KO mice
was clearly consistent with this in vitro effect, although it is
Figure 3. Expression of A2A receptor and oste-
oclast differentiation markers mRNA. A: Fold
change in A2A receptor mRNA in M-CSF–RANKL
OCPs during the 7 days of osteoclast differenti-
ation in the presence of CGS21680 alone or with
ZM241385. B: Fold change from control in ca-
thepsin K mRNA in M-CSF–RANKL–treated OCPs
during the 7 days of osteoclast differentiation in
the presence of CGS21680 alone or with
ZM241385. C: Fold change in NFATc1 mRNA in
M-CSF–RANKL–treated OCPs during the 7 days
of osteoclast differentiation in the presence of
CGS21680 alone or with ZM241385. D: Fold
change in osteopontin mRNA in M-CSF–RANKL–
treated OCPs during the 7 days of osteoclast
differentiation in the presence of the A2A agonist
alone or with ZM241385. ***P  0.005.possible that indirect effects of adenosine receptor dele-
was de
tures. O
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could have been responsible for the increase in oste-
oclasts observed. Even if adenosine receptors on other
cell types (eg, osteoblasts or inflammatory cells) play a
role in the A2A receptor–mediated regulation of osteoclast
formation in vivo, the direct effects of adenosine A2A re-
ceptor engagement on osteoclast differentiation remain
critical to the observed changes in osteoclast number
and bone resorption. The use of selective cell-specific
knockouts could have more definitely demonstrated that
the observed changes were only the result of the effects
on OCPs.
The order of affinity of adenosine receptors for aden-
osine is A1A2AA2B  A3; thus, as previously ob-
served by Yang et al,43 endogenous adenosine levels are
more potent stimuli for A1 and A2A receptors than A2B or
A3 receptors. The potency of adenosine as an agonist for
adenosine receptors also depends on the density of the
receptors.44 Under physiological conditions, adenosine
levels in most tissues are low but are sufficient to partially
activate A1, A2A, and A3 receptors, which are abundantly
expressed and highly sensitive. Based on the capacity of
the A2A antagonist to increase osteoclast formation and
function, it is likely that A2A receptors are activated by
endogenous levels of adenosine (as are A1 receptors).
Because A1 and A2A receptors have mutually antago-
nistic actions, it is likely that blockade of A2A receptors
permits full activation and signaling of A1 receptors by
endogenous adenosine. Similarly, blockade of A1 re-
ceptors may uncover endogenous activation of A2A
Figure 4. Morphological characterization of osteoclast cultures. A: Morpholo
cultured on glass. B: Quantitative evaluation of the number of least mature,
or in the presence of ZM241385 compared with control cultures. C: F-actin
CGS2160 alone or in the presence of ZM241385 compared with control culreceptors.Pellegatti and colleagues45 recently reported that the
purinergic axis plays a crucial role in osteoclast formation
and confirms previous evidence advocating a key role for
either ATP or adenosine receptors in multinucleated giant
cell formation. Although a message for adenosine recep-
tors was present in peripheral blood OCPs, an adenosine
A1 receptor message was present at low levels. Surpris-
ingly, Pellegatti and colleagues found that ATP, which
activates P2X7 receptors, blocks osteoclast fusion and
that catabolism of adenine nucleotides promotes oste-
oclast formation from precursors in peripheral blood, an
effect they ascribed to A2A receptor activation by its
selective agonist, CGS21680. However, in their work,
blockade or stimulation of adenosine receptors regulates
cellular fusion only when the P2X7 receptor is blocked or
adenine nucleotides are catabolized. This work stands in
contrast to prior work by Merrill and coworkers,24 in which
adenosine A1 receptor stimulation promotes multinucle-
ated giant cell formation and A2A receptor stimulation
inhibits fusion of peripheral blood monocytes. The differ-
ence between their findings in human peripheral blood
OCPs and the findings reported herein may be due to a
species-dependent difference in response to A2A recep-
tor stimulation. Another explanation may be that OCPs in
peripheral blood differ from precursors in the marrow with
respect to P2X7 or adenosine receptor expression or
function.
During osteoclast maturation, proinflammatory cyto-
kines cause an imbalance in bone metabolism favoring
bone resorption.46 Indeed, even in the absence of
aracteristics of the least mature (A), maturing (B), and mature (C) osteoclasts
g, and mature osteoclasts in osteoclast cultures treated with CGS2160 alone
tected by Alexa 555–phalloidin staining in osteoclast cultures treated with
riginal magnification for all parts, 63. ***P  0.005.gical ch
maturinRANKL-TNF–related activation-induced cytokine, TRAF6,
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well-documented inhibitory effects of adenosine A2A re-
ceptor stimulation on TNF- and IL-1 secretion probably
contribute, in our work, to inhibition of osteoclast formation
and bone resorption in inflammatory diseases and help
explain the therapeutic effects of methotrexate, the anti-
inflammatory effects of which are mediated by adenosine
acting at its receptors48 in the treatment of rheumatoid ar-
thritis. Thus, it is likely that, under inflammatory conditions,
the net effect of adenosine A2A receptor stimulation will be
even further inhibition of osteoclast formation.
Adenosine is a potent biological mediator that affects
numerous cell types, including neuronal cells, platelets,
neutrophils, and smooth muscle cells, among others.
Adenosine A2A receptors are coupled to GS and signal,
primarily by activation of adenylate cyclase, accumula-
tion of cAMP, and downstream activation of either protein
kinase A or exchange protein activated by cAMP. Signal-
ing downstream from protein kinase A proceeds, in part,through phosphorylation of the cAMP response element
binding transcription factor, resulting in activation leading
to either interaction of cAMP response element binding
with specific promoters and gene expression or compe-
tition with NF-B or other transcription factors. Prior re-
ports49 had suggested that increases in cAMP inhibited
osteoclast formation, but inhibition of protein kinase A
had no effect on osteoclastogenesis. Similarly, Lerner et
al50 detected the presence of functional A2 and P-site
receptors, but not A1 receptors, in mouse calvaria and
osteoblast-like cells; both receptors regulate cAMP, but
the authors assumed they were not intimately linked to
bone. Recently, Zhang et al51 linked the stimulation of
adenylyl cyclase by A2A and A2B activation, which led to
increased cAMP levels that, in turn, activated the canon-
ical protein kinase A pathway and the exchange protein
directly activated by cAMP52; in contrast, A1 and A3 ac-
tivation diminishes cAMP.53 In addition, adenosine re-
Figure 5. Cytokine secretion changes during
osteoclast differentiation. A: IL-1–secreted val-
ues during the 7 days of osteoclast differentia-
tion in WT M-CSF–RANKL cultures in the pres-
ence of CGS21680 alone or with ZM241385,
compared with control. B: TNF-–secreted val-
ues during the 7 days of osteoclast differentia-
tion in WT M-CSF–RANKL cultures in the pres-
ence of CGS21680 alone or with ZM241385,
compared with control. C: IL-1–secreted values
during the 7 days of osteoclast differentiation in
A2AKO M-CSF–RANKL cultures in the presence
of CGS21680 alone or with ZM241385, com-
pared with control. D: TNF-–secreted values
during the 7 days of osteoclast differentiation in
A2AKO M-CSF–RANKL cultures in the presence
of CGS21680 alone or with ZM241385, com-
pared with control. E: M-CSF–RANKL–derived
osteoclast treated with CGS21680 alone or with
ZM241385 in the presence of IL-1 were fixed
and stained for TRAP. F:M-CSF–RANKL–derived
osteoclasts treated with CGS21680 alone or with
ZM241385 in the presence of TNF- were fixed
and stained for TRAP. ***P  0.005.ceptor signaling in mast cells has also been linked to
aldehyd
and alc
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phosphatidylinositol 3-kinase (A3), and protein kinase C
and mitogen-activated protein kinases (A1, A2A, and A3
receptors).21 Future experiments will be directed at the
dissection of adenosine receptor signaling in OCPs and
the role of cAMP or other intermediates in the regulation
of osteoclast formation.
In rheumatoid arthritis and other inflammatory diseases
that affect the bone, there is inflammation of surrounding
tissues with activation of osteoclasts and resorption of
Figure 6. Decreased bone mass in adenosine A2AKO mice. Histological and
high-resolution microfocal CT images showing significantly greater trabecul
Three-dimensional panel reconstruction of the femurs revealed increased
histological sections obtained from the femurs of WT and A2AKO mice, stain
C: Osteoclast number/BV and BV/trabecular BV (TV) in WT and A2AKO mi
femurs from WT and A2AKO mice after fixation in 2.5% PFA plus 0.5% glutar
and embedded in Epon, divided into sections, and stained with lead citrate
Table 1. Histomorphometric Examination of Long Bones in
4-Month-Old WT and A2AKO Mice
Variable WT mice A2AKO mice
BV/tissue volume ratio 22.61  2.154 17.49 0.98*
Trabecular no.
(mm1)
5.8  0.07 4.4 0.15**
Trabecular separation
(m)
0.13  0.004 0.19 0.006**
Cortical area (mm2) 0.68  0.04 0.6  0.016*
Total area (mm2) 1.5  0.03 1.3 0.02*
BMD (HA/cm3) 0.053  0.0025 0.049  0.0016***
BMC (g) 0.48 0.051 0.43 0.028***
Outer perimeter (mm) 4.6 0.04 4.4 0.04***
TMC (g) 1.9  0.12 1.7 0.05*
TRAP-positive
osteoclasts (no./lpf)
35  1 50  13***
Data are expressed as the mean  SEM of three independent animals
and related to control.
*P  0.5, **P  0.005, and ***P  0.01.
BMC, bone mineral content; HA, hydroxyapatite; lpf, low-power field;
TMC, trabecular mineral content.bone. Adenosine A2A receptors have diminished inflam-
mation for a long time by directly inhibiting the inflamma-
tory function of macrophages, dendritic cells, and neu-
trophils and by stimulating anti-inflammatory functions of
macrophages and T cells.54 Moreover, methotrexate,
which diminishes inflammation by increasing extracellu-
lar adenosine concentrations,55 diminishes bone ero-
sions in rheumatoid arthritis, although not as well as anti-
TNF agents.
Because adenosine mediates the anti-inflammatory ef-
fects of methotrexate,56 we further speculate that the
capacity of methotrexate to inhibit bone erosion in pa-
tients with rheumatoid arthritis may be mediated by meth-
otrexate-stimulated increases in adenosine concentra-
tion. In KO mouse models, the A2A receptor, together with
the A3 receptor, mediated the anti-inflammatory effect of
methotrexate, which is used as a treatment of arthri-
tis.57,58 We first determined whether methotrexate in-
duced an increase of extracellular adenosine via intra-
cellular adenosine production or whether it was
generated extracellularly from adenine nucleotides. The
pathway leading to increased extracellular adenosine by
methotrexate has been mostly delineated in studies56–58
that confirmed that low-dose methotrexate therapy in-
creases tissue aminoimidazole carboxamide ribonucle-
otide (an intermediate in the generation of inosine mono-
phosphate) levels in animal models of rheumatoid
arthritis and urinary aminoimidazole carboxamide ribonu-
cleotide levels in patients with psoriasis and rheumatoid
rphometric analysis of the femurs of A2AKO and WT mice. A: Representative
ortical bone density in 4-month-old A2AKO mice compared with WT mice.
ass in A1KO mice compared with their WT littermates. B: Representative
AP activity as a marker of osteoclasts and counterstained with hematoxylin.
are from representative sections from transmission electron microscopy of
e in 0.05 mol/L sodium cacodylate buffer, postfixed in 1% osmium tetroxide
oholic uranyl acetate. **P  0.01.histomo
ar and c
bone m
ed for TR
ce. Dataarthritis.
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includes activation of the NF-B complex, NFATc1 tran-
scription factor, C-Jun kinase, p38, and extracellular sig-
nal regulated kinase mitogen-activated protein kinases
and the phosphatidylinositol 3-kinase–Akt axis.59,60 Each
of these pathways plays a key role in osteoclast differen-
tiation and/or function. Thus, mice lacking the p50 and
p52 subunits of NF-B or c-Fos, a member of the AP-1
family of transcription factors and a downstream target of
stress-activated protein kinase/C-Jun kinase, generate
no osteoclasts.61 Ectopic expression of NFATc1 in bone
marrow macrophages induces the formation of multinu-
clear osteoclasts in the absence of known fusion-induc-
ing factors, such as RANKL.62 In addition, adenosine A2A
receptor activation increases mitogen-activated protein
kinase phosphorylation and activation and activation of
AKT, Cdc42, and other pathways.63–65 The interactions
of adenosine A2A receptors with these signaling path-
ways in the formation and function of osteoclasts and in
the final mechanism of the differentiating phenotype need
further investigation.
In conclusion, these results indicate that adenosine
A2A receptors inhibit M-CSF–RANKL–stimulated oste-
oclast differentiation and function and, thereby, regulate
bone turnover.
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